Journal
NUCLEIC ACID THERAPEUTICS
Volume 23, Issue 6, Pages 443-449Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/nat.2013.0437
Keywords
-
Funding
- Korea Ministry of Environment as EI project'' [ERL E211-41003-0007-0]
- Agency for Defense Development through Chemical and Biological Defense Research Center [2012-0126-005]
- Korea Ministry of Environment as Converging Technology Project'' [212-101-004]
- MOTIE (The Ministry of Trade, Industry, and Energy)
- KIAT (Korea Institute for Advancement of Technology)
Ask authors/readers for more resources
Sensitive detection of the metabolites indicative of a particular disease contributes to improved therapy outcomes. Developing binding reagents for detection of low molecular weight metabolites is hampered by the difficulty with immobilization of targets through appropriate covalent chemical linkage while ensuring that selected reagents retain specificity to unmodified metabolites. To circumvent chemical modification of targets, we employed sol-gel droplets deposited onto a porous silicon chip to entrap a purine metabolite, xanthine, which was found at lower levels in urine samples from patients with non-Hodgkin lymphoma. By sol-gel SELEX (systematic evolution of ligands by exponential enrichment) against xanthine, specific aptamers (K-D approximate to 10M) with sensitivity of detection at as low as 1M were isolated, which bound to other purine metabolites at more than 100-fold lower affinity. In contrast, we failed to isolate xanthine-specific aptamers when SELEX was performed against xanthine covalently linked to polymer resin. This study demonstrates that the sol-gel platform for entrapping low molecular weight metabolites without chemical modifications can be utilized for SELEX to discover aptamers against clinical metabolite markers for diagnosis application.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available